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Abstract
CXCL10 (or Interferon-inducible protein of 10 kDa, IP-10) is an interferon-inducible chemokine with potent chemotactic
activity on activated effector T cells and other leukocytes expressing its high affinity G protein-coupled receptor CXCR3.
CXCL10 is also active on other cell types, including endothelial cells and fibroblasts. The mechanisms through which CXCL10
mediates its effects on non-leukocytes is not fully understood. In this study, we focus on the anti-proliferative effect of
CXCL10 on endothelial cells, and demonstrate that CXCL10 can inhibit endothelial cell proliferation in vitro independently of
CXCR3. Four main findings support this conclusion. First, primary mouse endothelial cells isolated from CXCR3-deficient
mice were inhibited by CXCL10 as efficiently as wildtype endothelial cells. We also note that the proposed alternative splice
form CXCR3-B, which is thought to mediate CXCL10’s angiostatic activity, does not exist in mice based on published mouse
CXCR3 genomic sequences as an in-frame stop codon would terminate the proposed CXCR3-B splice variant in mice.
Second, we demonstrate that human umbilical vein endothelial cells and human lung microvascular endothelial cells that
were inhibited by CXL10 did not express CXCR3 by FACS analysis. Third, two different neutralizing CXCR3 antibodies did not
inhibit the anti-proliferative effect of CXCL10. Finally, fourth, utilizing a panel of CXCL10 mutants, we show that the ability to
inhibit endothelial cell proliferation correlates with CXCL10’s glycosaminoglycan binding affinity and not with its CXCR3
binding and signaling. Thus, using a very defined system, we show that CXCL10 can inhibit endothelial cell proliferation
through a CXCR3-independent mechanism.
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Introduction
Chemokines are a superfamily of chemotactic cytokines, which
play important roles in the generation and delivery of immune and
inflammatory responses [1–3]. They orchestrate the movement of
leukocytes and other cells by activating specific seven-transmem-
brane spanning G protein-coupled receptors expressed on
responsive cells. CXCL10, or IP-10 (Interferon-induced protein
of 10 kDa), one of the first chemokines identified [4,5], directs the
trafficking of activated effector CD4
+ and CD8
+ T lymphocytes
and other effector lymphocytes, such as NK and NKT cells [6–9].
It does so by binding its high affinity receptor CXCR3 [10,11],
which it shares with two other ligands, monokine-induced by c-
interferon (Mig/CXCL9) and interferon-inducible T cell-a
chemoattractant (I-TAC/CXCL11). CXCL10 expression is
strongly up-regulated in many human inflammatory diseases,
including viral, bacterial and parasitic infections, skin diseases,
atherosclerosis, allograft rejection, and others [1].
In addition to its role in the activation and recruitment of
effector T cells and other leukocytes, CXCL10 acts on other cell
types, in particular on endothelial cells. Indeed, among the first
described functions of CXCL10 were its anti-proliferative effect on
endothelial cells in vitro [12], and its angiostatic [13–15] and anti-
tumor effect in vivo [6,16]. In vivo CXCL10 inhibits neovascular-
ization in tumors as well as wound healing [17–21]. The
mechanisms by which CXCL10 exerts its effects on endothelial
cells have remained elusive and in some instances controversial.
The identification of an alternative splice variant of CXCR3,
termed CXCR3-B, specifically in human endothelial cells, was
suggested as a possible explanation for CXCL10’s angiostatic
effects [22]. Translation of the putative human CXCR3-B splice
variant results in an extracellular N-terminus that is 48 amino
acids longer than the originally described CXCR3 receptor
(referred to as CXCR3-A), with the remaining 39 sequence
identical to CXCR3-A. The traditional CXCR3 ligands,
CXCL10, 9 and 11, were shown to bind to CXCR3-B. In
addition, CXCL4 (Platelet Factor 4, PF4), was also shown to
weakly bind CXCR3-B. CXCR3-B has been described to mediate
the angiostatic effect of its ligands, being the preferential CXCR3
receptor reported to be expressed on endothelial cells. Strikingly,
overexpression of CXCR3-B in an endothelial cell line resulted in
CXCL10 inhibiting proliferation, whereas overexpression of
CXCR3-A in the same cell line resulted in CXCL10 augmenting
proliferation [22].
Although the existence of an alternative splice variant CXCR3
provides a possible explanation for the different functions of
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12700CXCL10, it is unclear how a difference in only the N-terminal
extracellular domain of CXCR3-A results in intracellular signaling
that was purported to oppose CXCR3-A signaling. In addition, it
has been unclear whether CXCR3-B exists in rodents, although
CXCL10’s anti-proliferative effects on endothelial cells have been
described in mice. We therefore utilized a very defined in vitro
system to address whether the anti-proliferative effect of CXCL10
on endothelial cells is mediated through CXCR3. We demonstrate
that CXCL10 was capable of inhibiting the proliferation of murine
endothelial cells that were deficient in CXCR3. Furthermore, we
show that the alternative CXCR3-B variant does not exist in mice,
as an in-frame stop codon before the conserved sequence would
terminate an analogous CXCR3-B splice variant in mice.
Similarly, our experiments with human endothelial cells also
demonstrate that CXCL10 can inhibit endothelial cell prolifera-
tion independently of CXCR3.
Results
CXCL10 inhibits proliferation of endothelial cells isolated
from different tissue
We tested CXCL10’s effect on the proliferation of three
primary endothelial cell types, human umbilical cord endothelial
cells (HUVEC), human lung microvascular endothelial cells
(HMVEC-L), and murine heart endothelial cells isolated from
C57Bl/6 mice. As has been described [12], at relatively high
concentrations, CXCL10 inhibited bFGF-induced proliferation
for all three endothelial cell types, with concentrations of 0.5–
1.0 mM CXCL10 inhibiting 50% of proliferation, whereas 5.0 mM
inhibited 80% of proliferation (Fig. 1). The IC50 value for
CXCL10’s antiproliferative effect therefore is between 0.5–
1.0 mM, similar to Lasagni et al. who reported peak inhibition of
HMVEC proliferation at 100 nM–1 mM CXCL10 [22], and
similar to the IC50 value of ,150 nM that we previously reported
[12]. These results demonstrate that at relatively high concentra-
tions, CXCL10 can inhibit multiple types of endothelial cells.
CXCL10 anti-proliferative effect on murine endothelial
cells is CXCR3 independent
To directly test whether the anti-proliferative effect of CXCL10
requires CXCR3, we isolated endothelial cells from the hearts of
wildtype and CXCR3-deficient (CXCR3 KO) C57Bl/6 mice.
Endothelial cells were isolated using PECAM-1-coated microbe-
ads, with a second selection utilizing ICAM-2-coated microbeads
if needed. Endothelial cells were used for proliferation assays only
if their purity was at least 85%, with purity levels often reaching
over 90% (see Fig. 2A). CXCL10’s anti-proliferative effect on
bFGF-induced proliferation on primary heart endothelial cells was
measured between passage 2 and 3. Both wildtype and CXCR3-
KO endothelial cell proliferation were effectively inhibited by
CXCL10 (Fig. 2B), clearly showing that CXCL10 can exert its
anti-proliferative effect through a CXCR3-independent mecha-
nism. We also analyzed the expression of CXCR3 on heart
endothelial cells by flow cytometry and found no expression of
CXCR3 on wildtype cells (Fig. 2C). In contrast, activated murine
wildtype CD4+ Th1-type T cells expressed high levels of CXCR3.
The alternative CXCR3-B splice variant does not exist in
mice
Since CXCL10 has angiostatic effects in mice as well as on
human endothelial cells, we wanted to know whether alternative
splicing could result in a CXCR3-B splice variant in mice. Both
human and murine CXCR3 have a splice donor site six base pairs
(bp) after the initiating ATG, with a 978 bp intron and 1006 bp
intron, respectively, before the AG acceptor site (Fig. 3 A and B).
This splice variant produces the originally identified CXCR3
cDNA, which is now sometimes referred to as CXCR3-A. The
hCXCR3-B splice variant is produced by an alternative splice
between the same donor site used by CXCR3-A (Fig. 3A, position
80), and a different acceptor site located 233 bp upstream of the
AG acceptor site for CXCR3-A (position 814). Translation of this
mRNA could be initiated from an alternative ATG start codon
found within the intron of CXCR3-A (Fig. 3A, highlighted in
yellow, position 905), 151 base pairs upstream of the known AG
acceptor site used for intron splicing and in-frame with the
remaining 39 sequence of CXCR3-A. To determine whether a
possible alternative splice site in the murine genome could result in
a homologous CXCR3-B splice variant in mice, we analyzed the
nucleotide sequence of the murine gene upstream of the known
AG acceptor used for CXCR3-A splicing. For a homologous
CXCR3-B splice variant to exist in mice, the translation would
need to start with an initiating ATG in frame with the remaining
CXCR3 sequence, without a stop codon terminating translation.
In analogy with the human splice variant, we analyzed the 200
base pairs upstream from the murine acceptor site, and translated
the open reading frame that would be in frame with the remaining
39 translated sequence (Fig. 3B, frame 1). In this ORF, there is a
potential initiating ATG at position 948, but a stop codon at
position 1023 would prematurely terminate translation, and would
therefore not result in a CXCR3-B splice variant with an
alternative, longer N-terminal sequence. There are also a number
of other ATG codons upstream of the 2
nd exon of CXCR3-A, but
none of them are in frame with the remaining 39 translated
sequence (frame 2 and 3 in Figure 3B). Therefore, even if there
was an alternative acceptor splice site in mice, it would not result
in a translated CXCR3-B splice variant similar the one proposed
in humans.
Figure 1. CXCL10 inhibits proliferation of endothelial cells
isolated from different organs. Human umbilical cord vein
endothelial cells (HUVEC), human lung microvascular endothelial cells
(HMVEC-L), and murine heart endothelial cells isolated from C57Bl/6
mice were plated in 96-well plates with bFGF. 24 hr after seeding, new
media with CXCL10 was added and replaced every 48 hr for a total of
3–4 days.
3H-thymidine incorporation was assessed for the final 18 hr of
incubation. Representative data of at least three experiments are
shown, each performed in triplicate, data are mean 6 SD.
doi:10.1371/journal.pone.0012700.g001
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and murine CXCR3 genes to analyze which regions of the gene
are conserved between the two species. If an orthologue of
CXCR3-B were to exist in mice, a similar conservation would be
expected in the CXCR3-B coding sequence as in the CXCR3-A
coding sequences. We generated a dot matrix plot aligning the
hCXCR3 and mCXCR3 gene on an X–Y plot (Fig. 4), using a
window of 21 base pairs with a mismatch limit of 4. The conserved
regions between human and murine CXCR3 clearly match to the
59 region of exon 1, and the region of exon 2, starting at position
1066. In contrast, there is very low homology in the coding
sequence of the proposed elongated hCXCR3-B N-terminus
(starting at position 904), further suggesting that the murine gene
does not share a homologous CXCR3-B splice variant. Finally, we
performed a Blast search on the NCI EST (expressed sequence
tags) database for murine genes with the 150 base pairs upstream
of exon 2, which would be unique to a CXCR3-B splice variant,
and found no matching cDNA clones. In contrast, using the cDNA
sequence that crosses the first intron in the ‘‘traditional’’ CXCR3-
A variant from exon 1 into exon 2, four cDNA clones were
identified. Altogether, these three approaches strongly suggest that
the murine CXCR3 gene does not contain a CXCR3-B splice
variant similar to the one proposed in the human genome.
HUVEC and HMVEC-L do not express CXCR3 yet are
inhibited by CXCL10
There have been conflicting results about the expression of
CXCR3 by endothelial cells [23–26]. We therefore investigated
CXCR3 surface expression using flow cytometry on HUVEC and
HMVEC-L, two human endothelial cell preparations that are
sensitive to CXCL10’s antiproliferative effects (Fig. 1). We utilized
two different anti-CXCR3 antibodies: 1C6 from BD Bioscience,
directly conjugated to APC, which is commonly used to detect
CXCR3 expression on T cells; and an anti-CXCR3 antibody
from R&D (clone 49801), which has been reported to detect
CXCR3-B [22]. Since previous studies reported cell-cycle
dependent expression of CXCR3 [23,27], we analyzed CXCR3
expression on HUVEC and HMVEC-L harvested at high,
intermediate or low cell density. Finally, we also compared the
use of EDTA or Trypsin to release the endothelial cells from the
tissue culture plate, as Trypsin could potentially cleave CXCR3
expressed on the cell surface. The R&D anti-CXCR3 antibody
was not directly conjugated to any fluorophore, so cell binding was
detected with a secondary antibody conjugated to PE. Staining
HUVEC with the R&D antibody revealed a small shift in
fluorescence compared to cells stained with no antibody; however,
this shift was also present for cells stained with an isotype control
antibody, or for cells stained only with the secondary antibody
(Fig. 5A), clearly demonstrating that this small shift was not due to
CXCR3 expression. We then compared the staining of HUVEC
harvested at high, intermediate or low cell density, with either
EDTA or Trypsin, and found no CXCR3 expression under any of
these conditions (Fig. 5B–C). Similarly, staining of HMVEC-L, a
different primary endothelial cell preparation, with the R&D anti-
CXCR3 antibody, at different cell densities, utilizing either EDTA
(Fig. 5D) or Trypsin (not shown), also revealed no CXCR3
expression. In contrast, staining of activated human T cells with
the R&D anti-CXCR3 antibody demonstrated high levels of cell
surface CXCR3 expression (Fig. 5E). The same sets of
experiments were performed with the BD anti-CXCR3 antibody
(Fig. 5F–J). A small shift in fluorescence was observed staining
HUVEC with the BD antibody compared to the isotype control
antibody (Fig. 5F). There was some variability in the isotype
control background binding but in general this control antibody
had very low background binding most likely because it was a
directly conjugated antibody. We suspect that the slight shift of the
BD antibody compared to the isotype control does not represent
surface expression of CXCR3, and this slight shift was not
dependent on cell cycle, EDTA or Trypsin treatment (Fig. 5G–H).
For HMVEC-L, no shift in fluorescence was detected between the
anti-CXCR3 antibody and the isotype control antibody using the
BD antibody (Fig. 5I). In contrast, as a positive control, the BD
monoclonal antibody detected high levels of CXCR3 surface
expression on activated human peripheral blood T cells (Fig. 5J).
Expression of CXCR3 in HUVEC, HMVEC-L and T cells was
further investigated at the mRNA level by quantitative PCR, using
primers in the common region of exon 2 (forward primer position
Figure 2. CXCL10 inhibits proliferation of CXCR3-deficient
murine endothelial cells. A) Endothelial cells were isolated from
hearts of wildtype and CXCR3-deficient (CXCR3 KO) mice and purity was
determined by flow cytometry using antibodies against ICAM-2 and
PECAM-1. Endothelial cells of at least 85% purity were used for all
experiments. B) CXCL10’s anti-proliferative effect was assessed as
described for Figure 1. Representative data of at least three experiments
are shown, each performed in triplicate, data are mean 6 SD. C) CXCR3
expression of primary endothelial cells and activated T cells was
assessed by flow cytometry. Wildtype heart endothelial cells did not
express CXCR3, whereas activated wildtype T cells expressed high levels
of CXCR3.
doi:10.1371/journal.pone.0012700.g002
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In agreement with the flow cytometry data, HUVEC and
HMVEC-L, harvested at intermediate or high cell density, had
very low signal for CXCR3 mRNA, whereas T cells had a very
high signal for CXCR3 mRNA expression (Fig. 6). Together, these
data show that the same endothelial cells that were inhibited by
CXCL10 had no detectable CXCR3 mRNA or protein
expression.
CXCL10’s anti-proliferative effect is not neutralized by
two different anti-CXCR3 antibodies
We next tested the ability of the two neutralizing anti-hCXCR3
antibodies to inhibit CXCL10’s anti-proliferative effect on
HUVEC. Endothelial cells were incubated with the R&D
antibody (10 mg/ml or 50 mg/ml), the BD antibody (10 mg/ml)
or an isotype control antibody (10 mg/ml) for the duration of the
proliferation assay. The antibodies did not affect HUVEC
proliferation in the absence of CXCL10, and had no effect on
the ability of CXCL10 to inhibit HUVEC proliferation (Fig. 7A).
The neutralizing activity of these antibodies was confirmed by
their ability to inhibit chemotaxis of human T cells to CXCL10
(Fig. 7B). It is particularly important to note that the R&D anti-
CXCR3 antibody has been reported by Lasagni et al. to neutralize
CXCR3-B activity [22], yet in our hands, it did not inhibit the
anti-proliferative effect of CXCL10 on HUVEC. These findings
further support that CXCL10’s anti-proliferative effect on human
endothelial cells is not dependent on CXCR3.
CXCL10’s anti-proliferative effect correlates with
glycoaminoglycan binding rather CXCR3 binding
We next investigated the requirement of CXCR3 binding for
CXCL10’s anti-proliferative effect on HUVEC utilizing a series of
CXCL10 mutants we previously described [28]. In particular,
mutant R8A has greatly decreased CXCR3 binding affinity and
does not induce chemotaxis or calcium-flux through CXCR3
in vitro, or recruitment of T cells in vivo [29], whereas it binds
normally to glycosaminoglycans (GAGs). Mutant R8A was
however fully able to inhibit HUVEC proliferation to the same
extent as wildtype CXCL10 (Fig. 8), again suggesting that the anti-
proliferative effect of CXCL10 on endothelial cells in this assay is
not dependent on CXCR3 binding and signaling. In contrast,
mutant R22E, a partial CXCR3 agonist, but with markedly
reduced GAG binding affinity, had a minimal effect on HUVEC
proliferation even at the highest concentration tested. Consistent
with this, mutant CtR22A, which has four basic residues in the C-
terminal helix mutated to acidic residues (K71E/R72Q/K74Q/
R75E) as well as a mutation of R22A, and has very low GAG and
CXCR3 binding, also did not inhibit endothelial cell proliferation.
Taken together, these findings suggest that GAG binding rather
than CXCR3 binding is important for CXCL10’s anti-prolifera-
tive effect.
Discussion
CXCL10 is one of the most highly induced cytokines during
Th1-type inflammatory responses. CXCL10’s activity on effector
T lymphocytes and other leukocytes cells has been clearly
demonstrated to be mediated by activation of its high affinity G
protein-coupled receptor CXCR3. However, CXCL10 exerts
effects on cells other than leukocytes, including endothelial cells.
The mechanisms through which CXCL10 influences the activity
of these cell types is not entirely clear. We therefore focused our
study on the well-documented effect of CXCL10 on the
proliferation of endothelial cells, employing a defined in vitro assay
to study the anti-proliferative effect of CXCL10. Various
mechanisms have been suggested to explain this anti-proliferative
effect of CXCL10 on endothelial cells, including 1) signaling
through CXCR3 on endothelial cells, 2) competition with growth
factors for GAG binding, and 3) direct signaling of chemokines
through GAGs.
The hypothesis that CXCL10’s anti-proliferative effect on
endothelial cells is mediated by CXCR3 received wider accep-
tance after the identification of a proposed alternative splice
variant in humans called CXCR3-B, which was reported to
specifically mediate these effects of CXCL10 [22]. However, there
is still much debate whether CXCR3-B is indeed a functional
receptor that mediates differential functions in contrast to the
originally described CXCR3 (or CXCR3-A). Although a number
Figure 4. Homology of human and murine CXCR3 gene is
confined to CXCR3-A coding regions. A dot matrix of the human
CXCR3 and the murine CXCR3 gene was generated with the Dnadot
software (http://arbl.cvmbs.colostate.edu/molkit/dnadot/), with a win-
dow size of 21 and a mismatch allowance of 3.
doi:10.1371/journal.pone.0012700.g004
Figure 3. Alternative splice variant CXCR3-B does not exist in mice. A) human and B) murine CXCR3 schematic (top) and nucleotide
sequence (bottom). The genomic/unspliced and cDNA are shown for CXCR3-A and B. Thick bars represent translated exons, thin bars untranslated
exons, and thin lines introns. Regions common to both CXCR3-A and B are represented in black, regions that are specific for CXCR3-B in light grey.
The 59 region that is translated for CXCR3-A, but untranslated for CXCR3-A is shown in dark grey. CXCR3-A and CXCR3-B splice donor site is indicated
in green, CXCR3-A splice acceptor site in orange, proposed human CXCR3-B splice acceptor site in cyan. Initiating ATG codon for CXCR3-A is indicated
in red, and potential initiating ATG codons for CXCR3-B in yellow, with the proposed CXCR3-B ATG underlined. For human CXCR3, the primer pairs
used for detecting CXCR3-A [1F (forward) and 1R (reverse)] and CXCR3-B (2F and 2R) are indicated in the schematic. For murine CXCR3-B, nucleotide
sequence position 912–1112 was translated to assess whether CXCR3-B exists in mice using the Expasy Proteomics server (http://www.expasy.org/
tools/dna.html). Frame 1 is in-frame with the remaining 39 sequence, but a stop codon would terminate any possible murine CXCR3-B.
doi:10.1371/journal.pone.0012700.g003
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they mostly rely on the same primer pairs described in the original
publication by Lasagni et al. [22]. However, the CXCR3-B primer
pair used in these studies does not span an intron and therefore will
also detect and produce the same sequence for unspliced RNA. The
forward primer used for detecting CXCR3-B is located after the
alternative initiating ATG within the intron of CXCR3-A (position
1011–1029 within Pubmed gene reference NC_000023.10, see
Fig. 3A) and the reverse primer is located within the exon (position
1089–1070), resulting in a PCR product of 79 bp. To our
knowledge this fact has not been discussed in any prior publication.
In contrast, the primers commonly used to detect CXCR3-A
(including those used by by Lasagni et al.), span an intron; these
primers are located before the donor splice site for the forward
primer (position 40–58) and after the acceptor splice site (position
1128–1104). Importantly, this CXCR3-A primer pair should
therefore give a product for spliced CXCR3-A and CXCR3-B,
with a PCR product of 111 bp for spliced CXCR3-A and 355 bp
for spliced CXCR3-B. However, in most publications using
endothelial cells [22], tumor cells [30,31] and epithelial cells [32],
highlevelshavebeenreportedwiththeCXCR3-Bprimers,butvery
low levels with the CXCR3-A primers, which has led to the
conclusion that CXCR3-B is preferentially expressed on these cells.
The question remains though why in these publications the
CXCR3-A primers did not give a signal for CXCR3-B. We are
furthermore concerned that when we performed a Blast search on
the NCI EST (expressed sequence tags) database with the 59
nucleotide sequence unique to human CXCR3-B no matching
cDNA clones were identified in any of the published cDNA
libraries. In contrast, using the 59 cDNA sequence of human
CXCR3-A that crosses the firstintronina similarBlastsearch ofthe
NCI EST database, we identified 13 matching cDNA clones. In the
Figure 6. HUVEC and HMVEC-L have very low expression of
CXCR3 mRNA. HUVEC and HMVEC-L were harvested at two different
cell densities, and human peripheral blood T cells were harvested after
7 days in culture with IL-2. A primer pair in the common sequence in
exon 2 of CXCR3 was used to detect both CXCR3-A and B splice variants
using qPCR.
doi:10.1371/journal.pone.0012700.g006
Figure 5. HUVEC and HMVEC-L have no detectable surface CXCR3 expression. CXCR3 surface levels were assessed by flow cytometry using
anti-hCXCR3 monoclonal antibodies from R&D (A–E), or BD Bioscience (F–J), for HUVECS (A–C, F–H), HMVEC-L (D and I) and human peripheral blood T
cells cultured in IL-2 (E and J). Endothelial cells were harvested at different densities to determine cell cycle dependency of CXCR3 expression (B–C,
G–H), and were harvested either with EDTA (A, B, D, F, G, I) or trypsin (C and H).
doi:10.1371/journal.pone.0012700.g005
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identified a cloneina leukocytecDNA librarythatshowedcomplete
homology with CXCR3-B, but this library does not seem to be
available on-line anymore.
An important consideration regarding CXCR3-B is the
efficiency with which the spliced human CXCR3-B mRNA would
be translated. The first ATG codon within spliced CXCR3-B
mRNA is the same initiating ATG of CXCR3-A (see Fig. 3A,
highlighted in red). Since this is a strong Kozak consensus
sequence [33], translation should start at this position. There are
also two additional ATG codons before the proposed CXCR3-B
translational start. All three of these distal ATG codons (see
Fig. 3A, highlighted in yellow) have weaker Kozak sequences than
the upstream CXCR3-A ATG (Fig. 3A, highlighted in red). It is
therefore unlikely that translation would start at the proposed
CXCR3-B ATG. In fact, the presence of upstream ATG codons is
seen as a warning sign whether cDNA clones reflect a functional
mRNA [33]. Translation of the putative human CXCR3-B splice
mRNA is therefore expected to start at the CXCR3-A ATG
codon, but this translation would get terminated after 22 codons.
Theoretically, translation can get re-initiated, as eukaryotic
ribosomes can resume scanning and reinitiating translation
downstream of the stop codon [34]. The proposed CXCR3-B
translation start site is the next ATG after the stop codon and
could therefore result in re-initiation and translation of CXCR3-B.
However, re-initiating is inefficient, particularly as the upstream
open reading frame (ORF) lengthens past 13 codons, which in the
case of CXCR3-B is 22 codons (66 base pairs). Studies have shown
that very short upstream ORF (3–9 codons) reduced the yield to
30–35%, and 13–33 codons resulted in a further 3-fold lower
efficiency [34,35]. It is also important to note that the presence
and abundance of mRNA or cDNA transcripts do not
unequivocally establish the presence of functional mRNA and its
efficient translation [33]. Indeed, many immature or partially
spliced mRNAs have been found in cDNA libraries, in particular
Figure 8. CXCL10’s anti-proliferative effect correlates with GAG
binding, but not CXCR3 binding. HUVEC were plated in 96-well
plates with bFGF. 24 hr after seeding, new media with CXCL10 (wt or
mutants) was added and replaced every 48 hr for a total of 3–4 days.
Mutant R8A is devoid of CXCR3 signaling, but has normal heparin
binding affinity. Mutant R22E has low heparin binding affinity and low
CXCR3 signaling, and mutant CtR22A has minimal CXCR3 signaling and
very low heparin binding affinity.
3H-thymidine incorporation was
assessed for the final 18 hr of incubation. Representative data of at least
three experiments are shown, each performed in triplicate, data are
mean 6 SD.
doi:10.1371/journal.pone.0012700.g008
Figure 7. Neutralization of CXCR3 does not diminish CXCL10’s anti-proliferative effect. A) HUVEC were plated in 96 well plates with bFGF.
24 hr after plating, new media with CXCL10 and anti-CXCR3 antibody from BD Bioscience (10 mg/ml) or R&D (10 or 50 mg/ml), or an isotype control
IgG (10 mg/ml).
3H-thymidine incorporation was assessed for the final 18 hr of incubation. Representative data of two experiments are shown, each
performed in triplicate, data are mean 6 SD. B) BD Bioscience and R&D neutralizing anti-CXCR3 antibodies block the ability of CXCL10 to induce
chemotaxis of human T cells. 100 ng/ml CXCL10 was placed in the bottom well of Neuropore chemotaxis chambers. Human T cells were pre-
incubated with 10 mg/ml antibody, and were added on top of the Neuroprobe membrane and allowed to migrate for 2 hours. Representative data
from two experiments are shown, each performed in duplicate, data are mean 6 SD.
doi:10.1371/journal.pone.0012700.g007
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cloning long transcripts. It has also been suggested that immature
RNA, and especially slow or only partial removal of the 59 intron
is a way to regulate mammalian gene expression [33]. With this in
mind, there is real concern whether CXCR3-B is expressed as a
functional protein in non-transfected cells and whether it is
expressed on the cell surface. The first publication by Lasagni et al.
[22] produced two anti-CXCR3-B specific monoclonal antibodies,
but these antibodies have not been made widely available, and
have only been used in a few publications. While we deliberately
chose not to focus our study on CXCR3-B, we do want to point
out these uncertainties about the CXCR3-B splice variant and
whether this variant explains the anti-proliferative and angiostatic
functions of CXCL10 in human cells.
A further open question has been whether CXCR3-B exists in
mice and other rodents. We have not found any published papers
directly referring to CXCR3-B in mice, although many studies
have reported angiostatic effects of CXCL10 in mice in vivo and
in vitro. Analyzing the murine CXCR3 gene based on published
sequences, we show here that a stop codon would terminate a
potential in-frame CXCR3-B splice variant. In support of this
conclusion, we found no sequences in the mouse EST database
matching the putative mouse CXCR3-B specific region. Even if
CXCR3-B mediates anti-proliferative effects in humans, there has
to be a different explanation for CXCL10’s angiostatic and anti-
proliferative effects in mice.
Due to the complexity of potentially different pathways being
involved in mediating CXCL10’s in vivo angiostatic effect, we
focused solely on the question on whether the in vitro anti-
proliferative effect of CXCL10 on endothelial cells requires
CXCR3. The clearest experiment to test the requirement of
CXCR3 was to utilize CXCR3-deficient endothelial cells derived
from mice in which the majority of exon 2 of the CXCR3 gene,
which encodes almost the entire protein, has been deleted. We first
showed that CXCL10 has the same anti-proliferative effect on
primary murine heart endothelial cells as on HUVEC and
HMVEC, the two main human endothelial cells used to
investigate CXCL10’s angiostatic effect. We next demonstrated
that CXCL10 inhibits CXCR3-deficient endothelial cells as
efficiently as wildtype endothelial cells, clearly pointing to a
CXCR3-independent pathway for this effect. It is interesting to
note though that various studies reported that the angiostatic effect
of CXCL10 was reduced in CXCR3-deficient mice. In particular
CXCR3-deficient mice displayed impaired post-ischemic neovas-
cularization [20], and delayed and impaired wound healing
[18,19]. However, CXCL10’s angiostatic effect in these models
might not primarily be mediated by its direct anti-proliferative
effects on endothelial cells, but mediated indirectly through its
effects on other CXCR3-expressing cells. Indeed, Waeckel et al.
demonstrated that in CXCR3-deficient mice, fewer T cells and
monocytes/macrophages accumulated after ischemic injury and
that transfer of wildtype bone marrow-derived mononuclear cells
restored the impaired neovascularization in CXCR3-deficient
mice, pointing to a leukocyte recruitment-dependent mechanism
contributing to CXCL10’s angiostatic effect in vivo [20].
We performed further experiments to test whether CXCL10’s
in vitro anti-proliferative effect on human endothelial cells is
CXCR3 dependent. First, we analyzed CXCR3 expression by
flow cytometry on the same endothelial cells that were inhibited by
CXCL10. In our hands, using two different CXCR3 blocking
antibodies, one of which was reported to detect CXCR3-B, we
were not able to detect significant expression of CXCR3 on
HUVEC or HMVEC-L. Quantitative PCR using primers specific
to sequence in exon 2 common to CXCR3-A and CXCR3-B also
revealed that HUVEC and HMVEC-L have very little, if any,
CXCR3 mRNA expression. Furthermore, the two antibodies did
not neutralize CXCL10’s anti-proliferative effect on HUVEC.
Both of these findings clearly point to a CXCR3-independent
mechanism, in agreement with the fact that CXCL10 inhibited
proliferation of CXCR3-deficient murine endothelial cells. Finally,
we utilized a series of CXCL10 mutants we generated to map the
CXCR3 and GAG binding sites of CXCL10 [28]. Mutant R8A,
which is devoid of CXCR3 signaling but with retained GAG-
binding, inhibited endothelial cell proliferation as well as wildtype
CXCL10, strongly suggesting again that this effect is CXCR3
independent. A similar finding was also reported by Proost et al.
with an N-terminally truncated CXCL10, which was devoid of
CXCR3 signaling but retained an angiostatic effect in the rabbit
cornea micropocket model [37]. In contrast, mutant R22E with
markedly reduced GAG-binding affinity, had a minimal effect on
HUVEC proliferation. This independent line of investigation
suggests that the ability of CXCL10 to inhibit endothelial cell
proliferation is more associated with its binding to glycosamino-
glycans than its binding to CXCR3.
Indeed, one of the first explanations for CXCL10’s and CXCL4
‘s anti-proliferative effect on endothelial was that they interfered
with the binding of growth factors to GAGs [12,38]. Growth
factors, in particular bFGF and VEGF, utilize GAG binding to aid
binding to their high affinity receptors [39]. CXCL4 anti-
proliferative effect has been clearly shown to include a component
related to competition of heparin binding as well as heparin
binding-independent components [40–43], which was however
not related to CXCR3-B [43]. Similarly, CXCL10’s strong
heparin binding affinity could interfere with the binding of growth
factors to GAGs, thereby not involving CXCR3.
A third possible mechanism suggested for CXCL10’s anti-
proliferative effect could be direct signaling through GAGs.
Chemokine binding to GAGs has been demonstrated to cause
direct signaling in a number of different studies. For example,
CCL5 (RANTES) has been shown to activated the phosphotyr-
osine kinase (PTK)-dependent and p44/p42 mitogen-activated
protein kinase (MAPK) signaling pathways through GAGs [44].
Similarly, the GAG component of the proteoglycan syndecan-4
has been identified as a signaling molecule for CXCL12 (SDF-1)
[45].
While we suspect a component of CXCL10’s antiproliferative
effect on endothelial cells is the result of its affinity for GAGs and
the resultant displacement of growth factors from the cell surface,
we cannot exclude other mechanisms that may also contribute to
its effects on endothelial cells. However, our data strongly suggest
that CXCL10 can inhibit the proliferation of endothelial cells
through a CXCR3-independent pathway, and that this should be




Mice were bred and maintained and experiments were
performed according to protocols approved by the Massachusetts
General Hospital Subcommittee on Research Animal Care under
the MGH institutional assurance number A3596-01.
Materials, cells and mice
Human umbilical vein endothelial cells (HUVEC) and human
lung microvascular endothelial cells (HMVEC-L) were obtained
from Lonza, cultured with complete Lonza EGM-2 (HUVEC) or
EGM-MV-2 (HMVEC-L) culture media and used between
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National Cancer Institute. Breeder pairs of CXCR3-deficient
(CXCR3 KO) mice were a kind gift from Dr. G. Gerard
(Children’s Hospital, Harvard Medical School, Boston, MA).
Recombinant CXCL10 (wildtype or mutant) was produced and
purified as described before [28]. Antibodies were from BD, unless
stated otherwise.
Isolation of primary heart endothelial cells
Heart endothelial cells were isolated from wildtype or CXCR3
KO C57Bl/6 mice as previously described [46,47], with slight
modifications. Briefly, hearts were removed after intracardial
perfusion with 30 ml of PBS, were cut very finely and digested for
45 minutes with 0.2% collagenase II (Roche) at 37uC with gentle
shaking. The tissue was disrupted further by gentle tituration with
a 14 g cannula and then filtered through a 70 mm cell strainer to
obtain single cell suspensions. The cells were incubated with sheep
anti-rat IgG Dynal beads (Dynal Corp), that were previously
coated with anti-PECAM-1 antibody (BD Biosciences), for 10
minutes at room temperature with end-over rotation. Bead-bound
cells were isolated with a magnetic separator, washed and plated
on gelatin-coated flasks in complete DMEM, supplemented with
20% fetal calf serum, 100 mg/ml porcine heparin (Sigma) and
100 mg/ml endothelial mitogen (Biomedical Technologies). When
the cells reached 70–80% confluency, the cells were detached with
trypsin-EDTA and washed. Purity was assessed by flow cytometry
using anti-murine PECAM-1-PE (BD Bioscience) and anti-murine
ICAM-2-FITC. If purity was below 80%, cells were further
purified by selection on anti-murine ICAM-2 antibody coated
Dynal-beads. Endothelial cells over 85% purity were used for
experiments between passage 2–3.
Proliferation assay
Endothelial cells (HUVEC, HMVEC, primary murine heart
endothelial cells) were plated into 96-well plates at densities of 1–
4610
3/well in their respective media, with only bFGF as the
growth factor at 5 ng/ml initially (R&D) [12,38], and then at the
concentration provided for in the Lonza EGM media kit without
heparin supplementation in later experiments as this did not affect
our results. One day after seeding the cells, the media was
removed and replaced with media containing CXCL10. Two days
later, the media was removed and replaced with fresh media
containing CXCL10. The cells were cultured with CXCL10 for a
total of 3–4 days, and [
3H]-thymidine (NEN, 1 mCu/well) was
added for the last 18 hr of incubation.
Flow cytometry
Surface levels of CXCR3 protein on human endothelial cells or
T cells was analyzed by flow cytometry, using two different
antibodies. The first was an anti-hCXCR3 monoclonal antibody
from R&D (clone 49801), used at 2 mg/stain, employing a mIgG1
isotype control (R&D), also at 2 mg/stain. The cells were
incubated with the primary antibody for 25 min, washed and
stained with a secondary goat- anti-mouse-PE labeled antibody
(Caltag Laboratories, 2 ml/stain) for 20 min. The second antibody
used to detect CXCR3 expression was a directly conjugated anti-
hCXCR3 antibody from BD Bioscience (1C6, APC-conjugated,
10 ml/stain), employing a mIgG1-APC isotype control (BD
Bioscience), staining the cells for 20 min. For CXCR3 expression
experiments, endothelial cells were grown at three different
densities, and harvested either with 0.25% trypsin or with
20 mM EDTA, between passage 3–6. Human T cells were
purified with anti CD3-MACS beads (Milteny Biotech) and grown
in complete RPMI, 10% FCS and hIL-2 (PeproTech) for 6–8
days.
Surface levels of CXCR3 protein on murine cells was analyzed
using an anti-CXCR3-PE conjugated antibody from R&D
(FAB1685P, 10 ml/stain). Murine endothelial cells were purified
as described above. Murine T cells were isolated from the spleen
and lymph nodes of wildtype and CXCR3-deficient C57Bl/6 mice
with anti CD4 Dynal beads and grown under Th1 conditions with
anti-CD3, anti-CD28, anti-IL-4, IL-12 and IL-2 for six days.
Endothelial cells and T cells were stained with anti-CXCR3-PE
antibody for 20 minutes, washed and flow cytometry was
performed on a FACS Calibur and analyzed with Flow Jo
software.
Chemotaxis
Chemotaxis assays were performed as described [28]. Briefly,
chemokine dilutions were added to the bottom well of a 96-well
chemotaxis plate (NeuroProbe, 5 mm pore size). Human T cells
were pre-incubated with anti-hCXCR3 antibody (R&D or BD,
10 mg/ml) or an isotype control (10 mg/ml) for 10 minutes and
then added on top of the membrane (2.5610
4 cells) and allowed to
migrate to CXCL10 (100 ng/ml) at 37uC for 2 h, after which cells
in the bottom wells were counted under a microscope. The
Chemotactic Index was calculated by dividing the number of cells
that migrated in the presence of chemokine by the number of cells
in the presence of buffer only.
Quantitative PCR
Total RNA from HUVEC, HMVEC-L and human T cells
prepared as above was isolated with an RNAeasy kit (Qiagen),
converted to cDNA and analyzed by qPCR as described [48]
using the MX4000 multiplex quantitative PCR system (Strata-
gene).
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